Skip to content

TuHURA Biosciences, Inc. HURA Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-13.4%-6.1pp
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-2.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-3.8%-1.6pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-63.1%-29.0pp
Janux Therapeutics logo
Janux TherapeuticsJANX
-9.3%-17.1pp

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s free cash flow yield?
TuHURA Biosciences, Inc. (HURA) reported free cash flow yield of -27.1% in Q1 2026.
How has TuHURA Biosciences, Inc.'s free cash flow yield changed year-over-year?
TuHURA Biosciences, Inc.'s free cash flow yield decreased by 168.1% year-over-year, from -10.1% to -27.1%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.